Jazz Pharmaceuticals

Jazz Pharmaceuticals plc, founded in 2003, has established its headquarters in Dublin, Ireland. As a key player in the biopharmaceutical industry, the company is primarily engaged in the development and commercialization of medical solutions across several therapeutic areas, including sleep medicine, hematology/oncology, pain management, and psychiatry. Among its prominent products, Xyrem (sodium oxybate) stands out as a significant treatment for narcolepsy. Jazz Pharmaceuticals also offers Defitelio (defibrotide sodium) for the treatment of severe hepatic veno-occlusive disease, and Vyxeos (daunorubicin/cytarabine), which addresses certain types of acute myeloid leukemia. The company's reach extends globally, with the United States being one of its major markets. In addition to the U.S. market presence, it operates in numerous European countries and continues to sell its products and services worldwide. (Powered by AI)